Merck said Q4 FY 2025 net sales were EUR 5.2 billion (-3.1% YoY), with organic sales growth of +2.6%. EBITDA pre in Q4 was EUR 1.4 billion (-3.2% YoY), with organic EBITDA pre growth of +3.1%, and EPS pre was EUR 1.88 (-9.2% YoY). Net income in Q4 was EUR 319.2 million (-52.1% YoY). For FY 2025, Merck reported net sales of EUR 21.1 billion (-0.3% YoY) and EBITDA pre of EUR 6.1 billion (+0.6% YoY), with EPS pre of EUR 8.34. By sector in Q4, Life Science net sales were EUR 2.3 billion (-2.2% YoY), with Process Solutions net sales of EUR 972.5 million (+3.7% YoY; +9.7% organic) and Science & Lab Solutions net sales of EUR 1.1 billion (-4.4% YoY; +1.2% organic). Healthcare net sales were EUR 2.2 billion (+2.5% YoY), including Mavenclad net sales of EUR 294.9 million (+9.3% YoY) and Glucophage net sales of EUR 251.6 million (+1.6% YoY), while Rebif net sales were EUR 108.8 million (-25.8% YoY) and Bavencio net sales were EUR 148.2 million (-19.3% YoY). Electronics net sales were EUR 805.3 million (-17.5% YoY), with the company citing solid double-digit growth in semiconductor materials while Delivery Systems & Services reached an expected trough; the quarter was also the first clean quarter following the divestment of Surface Solutions. Merck ended FY 2025 with net financial debt to EBITDA pre of 1.4x (Dec. 31, 2025) and proposed a stable dividend of EUR 2.20.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.
Comments